YON E Health raises €250K to develop tech that supports early detection and data-driven insights in women’s reproductive and vaginal health.
Contentlockr
Amsterdam-based YON E Health, a FemTech company, has raised €250K in pre-seed funding.
The investment will support the development of YON E Health’s smart vaginal health device that measures pH and temperature, two biomarkers linked to fertility, infection risk, and reproductive health.
The funds will also enable the company to move toward medical trials and further develop its device for clinical and consumer use.
The round was led by PMK-Group, led by Dr. Peter M. Kovacs.
PMK-Group operates as a strategic accelerator focused on health technologies. Dr. Kovacs, who holds a PhD in gynaecology, has developed one of the first private clinical research networks in Eastern Europe, centred on women’s health innovation, with connections across Europe and Asia.
Dr. Kovacs says, “YON E Health is addressing an area that’s both underserved and scientifically critical. Their approach, combining biosensor technology, clinical expertise, and user empathy, represents the future of proactive care in women’s health.”
Besides PMK-Group, the round also saw participation from UniPrisma Venture Studio, represented by Károly Szántó and Thijmen Meijer, who contributed to term sheet structuring and negotiation.
Matias Toye, founder of Oyster Shield and Dilicheck, assisted in mergers, acquisitions, and fundraising activities.
Advancing women’s health technology
Women’s health continues to receive limited financial attention relative to its global importance. According to a statement from YON E Health, less than 1 per cent of medical research funding focuses on women-specific conditions, and in 2024, only 2.3 per cent of VC investment supported female-founded startups. This funding gap has slowed work in areas including vaginal health, fertility, and menopause.
Founded in 2022 by Roswitha Verwer, YON E Health develops tools for vaginal and reproductive health based on real-time biological data.
Its first product is an at-home device that measures pH and basal body temperature, key indicators of fertility, infection risk, and vaginal health. The system provides science-based insights to help women track and manage their reproductive well-being through accessible data.
Roswitha Verwer says, “When I started YON E, I was told vaginal health was too taboo, too complex, and too ‘niche’ for innovation and investment. That’s what motivated and pushed me even more.”
“For too long, women have had to guess, self-diagnose, or wait until they show symptoms and something goes wrong with their health. We’re changing that, turning silence into data women can actually use.”
Currently, YON E Health operates across several regions, including Amsterdam, Budapest, London, Texas, Boston, and Madrid.
The role of vaginal pH
Vaginal pH reflects key aspects of reproductive and gynaecological health. Changes in acidity can indicate infection risk, hormonal variation, or fertility status. At present, most at-home pH testing relies on single-use paper strips applied after symptoms appear, which limits early detection and preventive care.
YON E Health has developed sensor-based technology that measures vaginal pH and basal body temperature together.
The system collects continuous data to help track menstrual cycle patterns, microbiome condition, and fertility timing. This information can support early identification of health imbalances and assist both users and clinicians in managing fertility and recurrent infection cases.
Dr. Muskaan Bhan, Chief Clinical Officer at YON E Health, says, “Vaginal health isn’t a luxury; it’s a foundation of overall wellbeing. Our technology bridges the gap between research and reality, empowering women globally with real-time, clinical-grade insights that can prevent complications before they start.”
